Heyu Biological Technology (OTCMKTS:HYBT – Get Free Report) and Vivani Medical (NASDAQ:VANI – Get Free Report) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.
Institutional and Insider Ownership
6.8% of Vivani Medical shares are held by institutional investors. 89.2% of Heyu Biological Technology shares are held by company insiders. Comparatively, 44.3% of Vivani Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Heyu Biological Technology and Vivani Medical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Heyu Biological Technology | $80,000.00 | 164.55 | -$270,000.00 | N/A | N/A |
| Vivani Medical | N/A | N/A | -$25.65 million | ($0.45) | -3.20 |
Risk and Volatility
Heyu Biological Technology has a beta of -17.74, meaning that its stock price is 1,874% less volatile than the S&P 500. Comparatively, Vivani Medical has a beta of 3.2, meaning that its stock price is 220% more volatile than the S&P 500.
Profitability
This table compares Heyu Biological Technology and Vivani Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heyu Biological Technology | -453.55% | -6.43% | -4.43% |
| Vivani Medical | N/A | -102.42% | -49.21% |
Analyst Recommendations
This is a summary of recent ratings for Heyu Biological Technology and Vivani Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heyu Biological Technology | 0 | 0 | 0 | 0 | 0.00 |
| Vivani Medical | 0 | 0 | 1 | 0 | 3.00 |
Vivani Medical has a consensus price target of $3.00, indicating a potential upside of 108.33%. Given Vivani Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Vivani Medical is more favorable than Heyu Biological Technology.
Summary
Vivani Medical beats Heyu Biological Technology on 6 of the 11 factors compared between the two stocks.
About Heyu Biological Technology
Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.
About Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
Receive News & Ratings for Heyu Biological Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heyu Biological Technology and related companies with MarketBeat.com's FREE daily email newsletter.
